<DOC>
	<DOCNO>NCT01980290</DOCNO>
	<brief_summary>The purpose study collect information efficacy , safety tolerability telaprevir ( combination medication ) , patient history intravenous drug use genotype 1 chronic hepatitis C , substitution therapy ( eg. , methadone , buprenorphine ) and/or follow addiction centre .</brief_summary>
	<brief_title>Telaprevir With Peginterferon Alfa &amp; Ribavirin Ex-People Who INject Drugs Infected Genotype 1 Chronic Hepatitis C</brief_title>
	<detailed_description>This multicenter , non-interventional , observational , prospective study evaluate efficacy , safety , adherence telaprevir ex-People Who Inject Drugs ( ex-PWIDs ) infect genotype 1 chronic hepatitis C fibrosis stage include compensated cirrhosis , receive substitution therapy ( eg , methadone , buprenorphine ) and/or follow addiction center . Patients may treatment naïve relapsers . Participating physician offer enrollment study eligible patient site plan initiate triple therapy telaprevir , pegylated interferon alfa ( PegIFN alfa ) , ribavirin ( RBV ) . A target 115 patient participate study . The duration patient 's participation study approximately 60 week . After obtain signed participation agreement ICF , selection criterion review verify patient 's eligibility . Data record electronic case report form ( CRF ) 6 time point patient correspond routine care visit : inclusion , patient 's routine care visit closest Week 4 , 12 , 24 , end treatment , end-of-follow-up ( e.g. , approximately 12 week end-of-treatment ) . No additional blood , urine , biological sample require , additional investigation , beyond routine clinical management patient , perform .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Have HCV genotype 1 , quantifiable serum HCV RNA , recent ( within 18 month baseline ) documentation degree liver fibrosis ( Metavir F0F4 ; Ishak 06 ) assess liver biopsy noninvasive test ( eg , fibrotest , fibroscan ) ; Physician decision start triple therapy telaprevir PegIFN alfa/RBV ; Have never treat antiviral treatment ( naïve ) relapse IFN PegIFN plus RBV ( relapsers ) ; History inject drug currently stable substitution therapy ( eg , methadone , buprenorphine ) and/or follow addiction center . Infected coinfected HCV genotype genotype 1 ; Previous current treatment DAA therapy ; Have contraindication specify SmPC telaprevir , PegIFN alfa , RBV ; Have history evidence decompensated liver disease , coinfection active hepatitis B HIV ; Currently participate another investigational study clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HCV genotype 1</keyword>
	<keyword>Liver Fibrosis</keyword>
	<keyword>ex-People INject Drugs ( ex-PWIDs )</keyword>
</DOC>